[go: up one dir, main page]

LV10192B - A slimming pharmaceutical composition - Google Patents

A slimming pharmaceutical composition Download PDF

Info

Publication number
LV10192B
LV10192B LVP-93-94A LV930094A LV10192B LV 10192 B LV10192 B LV 10192B LV 930094 A LV930094 A LV 930094A LV 10192 B LV10192 B LV 10192B
Authority
LV
Latvia
Prior art keywords
ephedrine
caffeine
agonist
vas
vere
Prior art date
Application number
LVP-93-94A
Other languages
English (en)
Latvian (lv)
Other versions
LV10192A (lv
Inventor
Astrup Arne
Original Assignee
Dak Lab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dak Lab As filed Critical Dak Lab As
Publication of LV10192A publication Critical patent/LV10192A/xx
Publication of LV10192B publication Critical patent/LV10192B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LVP-93-94A 1989-07-07 1993-02-03 A slimming pharmaceutical composition LV10192B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK339289A DK339289D0 (da) 1989-07-07 1989-07-07 Farmaceutisk praeparat
PCT/DK1990/000106 WO1991000730A1 (fr) 1989-07-07 1990-04-20 Composition pharmaceutique amincissante

Publications (2)

Publication Number Publication Date
LV10192A LV10192A (lv) 1994-10-20
LV10192B true LV10192B (en) 1995-06-20

Family

ID=8122369

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-94A LV10192B (en) 1989-07-07 1993-02-03 A slimming pharmaceutical composition

Country Status (19)

Country Link
US (1) US5422352A (fr)
EP (1) EP0480934B1 (fr)
JP (1) JP2584899B2 (fr)
KR (1) KR0159045B1 (fr)
AT (1) ATE107858T1 (fr)
AU (1) AU638992B2 (fr)
CA (1) CA2063598C (fr)
DE (1) DE69010336T2 (fr)
DK (2) DK339289D0 (fr)
ES (1) ES2055911T3 (fr)
FI (1) FI920026A7 (fr)
HK (1) HK1001821A1 (fr)
HU (1) HU220071B (fr)
LT (1) LT3536B (fr)
LV (1) LV10192B (fr)
NO (1) NO920051L (fr)
RU (1) RU2109511C1 (fr)
UA (1) UA27779C2 (fr)
WO (1) WO1991000730A1 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5865869A (en) * 1991-08-02 1999-02-02 Ecologel Usa, Inc. Solution for plant root watering
AU4659793A (en) * 1992-06-30 1994-01-24 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Anorectic epinephrine derivatives
AU682156B2 (en) * 1992-10-15 1997-09-25 Dana-Farber Cancer Institute, Inc. Treatment of insulin resistance in obesity linked type II diabetes using antagonists to TNF-alpha function
ES2094687B1 (es) * 1994-08-02 1997-12-16 S A L V A T Lab Sa Combinacion farmaceutica contra la obesidad o el sobrepeso.
FR2746644A1 (fr) * 1996-03-18 1997-10-03 Firion Jackie Produit parapharmaceutique moderateur d'appetit
DE69638106D1 (de) * 1996-09-30 2010-02-11 Dennis Jones Regulation von Körpergewicht durch Materialien basierend auf Zitrusvariationen
US6224873B1 (en) 1996-09-30 2001-05-01 Zhishin, Llc Regulation of appetite, body weight and athletic function with materials derived from citrus varieties
EP0946155B2 (fr) * 1996-12-23 2009-01-21 S.L.A. Pharma AG Composition pharmaceutique destinee au traitement de l'incontinence fecale
US5985282A (en) * 1997-01-22 1999-11-16 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
US6162455A (en) * 1997-01-22 2000-12-19 American Cyanamid Company Method for increasing lean meat, improving the lean meat to fat ratio and improving amino acid utilization in warm-blooded animals
US5798101A (en) * 1997-01-22 1998-08-25 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
HUP9700654A2 (hu) * 1997-03-26 1999-09-28 Dezső Korbonits Teobromin tartalmú köhögéscsillapító készítmények
US6468519B1 (en) * 1997-09-10 2002-10-22 Rutgers, The State University Of New Jersey Polyanhydrides with biologically active degradation products
US6277402B1 (en) 1998-06-26 2001-08-21 Delack Elaine Alice Method for treatment of multiple sclerosis and related disease states
US7232830B2 (en) 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
US6340482B1 (en) * 2000-05-18 2002-01-22 Zhishin, Llc Methods for inducing weight loss in a human with materials derived from Citrus varieties
US6113949A (en) * 1998-10-27 2000-09-05 Prolab Nutrition, Inc. Weight control product and method of treating hyperlipidemia and increasing vigor with said product
US6475514B1 (en) * 1998-12-03 2002-11-05 Andrew Blitzer Athletic patch
FR2788438B1 (fr) * 1999-01-14 2003-10-03 Arkopharma Laboratoires Composition pour le traitement de l'obesite et procede de traitement esthetique
US6576272B1 (en) * 1999-03-05 2003-06-10 Twin Laboratories Incorporated Dietary supplement and method of using same
WO2001005356A2 (fr) * 1999-07-20 2001-01-25 Natrol, Inc. Produit de surveillance de poids a base d'un melange synergique d'extrait de guggul, de sel de phosphate et un stimulant metabolique
WO2001013935A2 (fr) * 1999-08-23 2001-03-01 The Administrators Of The Tulane Educational Fund Modulation de transporteur de leptine a travers la barriere hemato-encephalique
US6723737B1 (en) * 1999-10-20 2004-04-20 Eliezer Rapaport Methods, pharmaceutical and therapeutic compostions for administering adenosine
US7115297B2 (en) * 2000-02-22 2006-10-03 Suzanne Jaffe Stillman Nutritionally fortified liquid composition with added value delivery systems/elements/additives
US7892586B2 (en) 2001-02-22 2011-02-22 Suzanne Jaffe Stillman Water containing soluble fiber
US8178150B2 (en) 2000-02-22 2012-05-15 Suzanne Jaffe Stillman Water containing soluble fiber
DE10011541A1 (de) * 2000-03-06 2001-09-20 Reimann Hartmut Verwendung einer Kombination aus Ephedrin und Coffein und/oder Theophyllin zur Vitalisierung von Knochenfischen, Wasserzusatz zur Vitalisierung von Knochenfischen
US6316499B1 (en) 2000-05-18 2001-11-13 Zhishin, Llc Methods for increasing the muscle mass of a human with materials derived from citrus varieties
WO2002051428A1 (fr) * 2000-12-25 2002-07-04 Shiseido Company, Ltd. Composition de parfum stimulant le systeme sympathique
US7048941B2 (en) * 2001-03-30 2006-05-23 New World Enterprizes, Inc. Chocolate composition as delivery system for nutrients and medications
US7041305B2 (en) * 2001-09-07 2006-05-09 Western Holdings, Llc Stable water in oil aminophylline emulsions
RU2209582C2 (ru) * 2001-10-22 2003-08-10 Горелик Самуил Лейбович Способ контроля веса пациента
GB0130763D0 (en) 2001-12-21 2002-02-06 Norgine Res Ltd Treatment methods
AU2003224507A1 (en) * 2002-04-19 2003-11-03 N.V. Nutricia Multiphasic diet
US8142810B2 (en) * 2002-05-30 2012-03-27 The Procter & Gamble Company Dietary method for modulating glucose metabolism and associated conditions and increasing longevity
US20040077530A1 (en) * 2002-10-18 2004-04-22 Robert Portman Composition for reducing caloric intake
US20040224031A1 (en) * 2003-05-06 2004-11-11 Antonio Zorzano Olarte Combination of amines and vanadium (IV)/(V) compounds for the treatment and/or prevention of diabetes mellitus
EP1672988A4 (fr) * 2003-10-17 2008-02-20 Diet Formulations Ltd Complement nutritionnel d'amaigrissement
NZ547178A (en) * 2003-11-20 2008-06-30 Alteragon Pty Ltd Method of decreasing fat deposits and body weight in mammals and birdsusing the R-isomer of Salbutamol
PL209905B1 (pl) * 2004-01-15 2011-11-30 Bringwell Internat Ab Preparat do leczenia otyłości i związanego z nią syndromu metabolicznego
CA2455248A1 (fr) * 2004-01-29 2005-07-29 Alexander Zolotoy Administration par voie orale de r-albuterol pour lutter contre l'obesite
US7524064B2 (en) * 2004-03-09 2009-04-28 Research Foundation Of The State University Of New York Apparatus and method for assessing retinal damage
US20060074057A1 (en) * 2004-10-04 2006-04-06 Eric Marchewitz Use of chenodeoxycholic acid for reducing adipose tissue
US20060134230A1 (en) * 2004-12-17 2006-06-22 Sal Abraham Weight loss composition and formulation
US20060204599A1 (en) * 2005-03-14 2006-09-14 Wheat Jared R Dietary supplement and method of using same
US20090214682A1 (en) * 2008-02-22 2009-08-27 Heuer Marvin A Composition and methods for weight loss in a subject
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
US9610429B2 (en) * 2010-12-29 2017-04-04 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue with targeted substance delivery
IN2015DN03188A (fr) 2012-10-08 2015-10-02 Rivalea Australia Pty Ltd
US9877434B2 (en) 2013-05-30 2018-01-30 Ecologel Solutions, Llc Granular compositions and methods for drought mitigation
NZ724579A (en) * 2014-03-26 2020-03-27 Rivalea Australia Pty Ltd Method for improving feed efficiency in ruminants
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
CN120436205A (zh) 2015-02-13 2025-08-08 马斯公司 包装宠物食物产品
WO2016167855A1 (fr) * 2015-04-14 2016-10-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Association d'albutérol et de caféine pour le traitement synergique de l'obésité ou de la sarcopénie
GB201522296D0 (en) 2015-12-17 2016-02-03 Mars Inc Food product to reduce body fat
AU2020276619A1 (en) * 2019-05-16 2021-12-16 Nexus Pharmaceuticals, Inc. Compositions comprising ephedrine or an ephedrine salt and methods of making and using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2390164A1 (fr) * 1977-05-13 1978-12-08 Blanie Paul Association a action anti-asthmatique
FI772858A7 (fi) * 1977-06-03 1978-12-04 Pharmaceutical Export Promotio Avmagningsmedel och foerfarande foer framstaellning daerav
US4364922A (en) * 1980-10-14 1982-12-21 University Of Virginia Alumni Patents Foundation Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
US5011843A (en) * 1988-05-31 1991-04-30 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors

Also Published As

Publication number Publication date
FI920026A0 (fi) 1992-01-03
EP0480934A1 (fr) 1992-04-22
DE69010336D1 (de) 1994-08-04
DK339289D0 (da) 1989-07-07
CA2063598C (fr) 1997-12-09
DE69010336T2 (de) 1994-11-03
NO920051D0 (no) 1992-01-03
AU638992B2 (en) 1993-07-15
KR0159045B1 (ko) 1998-12-01
HK1001821A1 (en) 1998-07-10
LV10192A (lv) 1994-10-20
HUT62798A (en) 1993-06-28
LT3536B (en) 1995-11-27
LTIP702A (en) 1995-01-31
UA27779C2 (uk) 2000-10-16
JPH04507091A (ja) 1992-12-10
DK0480934T3 (da) 1994-11-07
HU9200051D0 (en) 1992-06-29
CA2063598A1 (fr) 1991-01-08
FI920026A7 (fi) 1992-01-03
JP2584899B2 (ja) 1997-02-26
EP0480934B1 (fr) 1994-06-29
ES2055911T3 (es) 1994-09-01
HU220071B (hu) 2001-10-28
RU2109511C1 (ru) 1998-04-27
ATE107858T1 (de) 1994-07-15
WO1991000730A1 (fr) 1991-01-24
NO920051L (no) 1992-01-31
US5422352A (en) 1995-06-06
AU5630890A (en) 1991-02-06

Similar Documents

Publication Publication Date Title
US5422352A (en) Slimming pharmaceutical composition
HK1001821B (en) A slimming pharmaceutical composition
Powell et al. The influence of cigarette smoking and sex on theophylline disposition
US7867526B2 (en) Composition for weight reduction comprising capsaicin, green tea extract, L-tyrosine and caffeine
BENOWITZ et al. Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man
McCarty Homologous physiological effects of phenformin and chromium picolinate
Gong Jr et al. Bronchodilator effects of caffeine in coffee: A dose-response study of asthmatic subjects
JP3074519B2 (ja) 腸液吸収促進剤
KR20090032083A (ko) 신장 기능이 손상된 개체의 이뇨 작용 개선 방법
Prejbisz et al. Guidelines for the management of hypertension in Poland 2024—the position of the Polish Society of Hypertension/Polish Cardiac Society Experts
Volans Effects of food and exercise on the absorption of effervescent aspirin
WO2016167855A1 (fr) Association d'albutérol et de caféine pour le traitement synergique de l'obésité ou de la sarcopénie
Green et al. Metabolism of an oral tryptophan load. II: Effect of pretreatment with the putative tryptophan pyrrolase inhibitors nicotinamide or allopurinol.
JP4706174B2 (ja) α−グルコシダーゼ阻害剤
Dingemanse et al. Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects
Sponer et al. Drugs acting on multiple receptors: β-blockers with additional properties
Frank et al. Gout simulating cardiac pain∗
EP4545081A1 (fr) Ligand agissant sur des récepteurs d'adénosine et composition le comprenant pour la prévention, le soulagement ou le traitement de l'obésité
MacLennan et al. Metabolic and endocrine problems in the elderly
JP4604506B2 (ja) α−グルコシダーゼ阻害剤
SPONER et al. Drugs Acting on Multiple Receptors: ẞ-Blockers with Additional Properties
BR112019024373B1 (pt) Uso de teacrina e cafeína
Jones et al. Oxidation of dietary fat is decreased on an isocaloric saturated fat diet compared with a monounsaturated fat diet
DE FARMACOLOGIA BRITISH PHARMACOLOGICAL SOCIETY Joint meeting with
Yeung Laiwah Studies on the acute hepatic porphyrias